Literature DB >> 10544208

VEGF and vascular fusion: implications for normal and pathological vessels.

C J Drake1, C D Little.   

Abstract

The avian embryo is well suited for the study of blood vessel morphogenesis. This is especially true of investigations that focus on the de novo formation of blood vessels from mesoderm, a process referred to as vasculogenesis. To examine the cellular and molecular mechanisms regulating vasculogenesis, we developed a bioassay that employs intact avian embryos. Among the many bioactive molecules we have examined, vascular epithelial growth factor (VEGF) stands out for its ability to affect vasculogenesis. Using the whole-embryo assay, we discovered that VEGF induces a vascular malformation we refer to as hyperfusion. Our studies showed that microinjection of recombinant VEGF165 converted the normally discrete network of embryonic blood vessels into enlarged endothelial sinuses. Depending on the amount of VEGF injected and the time of postinjection incubation, the misbehavior of the primordial endothelial cells can become so exaggerated that for all practical purposes the embryo contains a single enormous vascular sinus; all normal vessels are subsumed into a composite vascular structure. This morphology is reminiscent of the abnormal vascular sinuses characteristic of certain neovascular pathologies. (J Histochem Cytochem 47:1351-1355, 1999)

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10544208     DOI: 10.1177/002215549904701101

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  25 in total

1.  Rho activity critically and selectively regulates endothelial cell organization during angiogenesis.

Authors:  Mien V Hoang; Mary C Whelan; Donald R Senger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

Review 2.  Multicellular sprouting during vasculogenesis.

Authors:  Andras Czirok; Evan A Zamir; Andras Szabo; Charles D Little
Journal:  Curr Top Dev Biol       Date:  2008       Impact factor: 4.897

3.  Matrix metalloproteinase 2-integrin alpha(v)beta3 binding is required for mesenchymal cell invasive activity but not epithelial locomotion: a computational time-lapse study.

Authors:  Paul A Rupp; Richard P Visconti; András Czirók; David A Cheresh; Charles D Little
Journal:  Mol Biol Cell       Date:  2008-10-15       Impact factor: 4.138

Review 4.  Endothelial Progenitor Cells for the Vascularization of Engineered Tissues.

Authors:  Erica B Peters
Journal:  Tissue Eng Part B Rev       Date:  2017-07-03       Impact factor: 6.389

5.  Intussusceptive microvascular growth in human glioma.

Authors:  Beatrice Nico; Enrico Crivellato; Diego Guidolin; Tiziana Annese; Vito Longo; Nicoletta Finato; Angelo Vacca; Domenico Ribatti
Journal:  Clin Exp Med       Date:  2009-10-31       Impact factor: 3.984

Review 6.  Angiogenesis.

Authors:  Donald R Senger; George E Davis
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-08-01       Impact factor: 10.005

7.  Knockdown of ezrin suppresses the migration and angiogenesis of human umbilical vein endothelial cells in vitro.

Authors:  Liang-Ping Zhao; Lei Huang; Xun Tian; Feng-Qi Liang; Jun-Cheng Wei; Xian Zhang; Sha Li; Qing-Hua Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-04-13

8.  To Fuse or Not to Fuse.

Authors:  Lisa J Simpson; Ellie Tzima
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-09       Impact factor: 8.311

9.  Identification of SOX9 interaction sites in the genome of chondrocytes.

Authors:  Chun-do Oh; Sankar N Maity; Jing-Fang Lu; Jiexin Zhang; Shoudan Liang; Francoise Coustry; Benoit de Crombrugghe; Hideyo Yasuda
Journal:  PLoS One       Date:  2010-04-09       Impact factor: 3.240

10.  Moderation of calpain activity promotes neovascular integration and lumen formation during VEGF-induced pathological angiogenesis.

Authors:  Mien V Hoang; Janice A Nagy; Joan E B Fox; Donald R Senger
Journal:  PLoS One       Date:  2010-10-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.